Twist1 and Twist2 Contribute to Cytokine Downregulation following Chronic NOD2 Stimulation of Human Macrophages through the Coordinated Regulation of Transcriptional Repressors and Activators

Shasha Zheng, Matija Hedl and Clara Abraham

*J Immunol* published online 27 May 2015
http://www.jimmunol.org/content/early/2015/05/27/jimmunol.1402808

Supplementary Material
http://www.jimmunol.org/content/suppl/2015/05/27/jimmunol.1402808.8.DCSupplemental

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Twist1 and Twist2 Contribute to Cytokine Downregulation following Chronic NOD2 Stimulation of Human Macrophages through the Coordinated Regulation of Transcriptional Repressors and Activators

Shasha Zheng, Matija Hedl, and Clara Abraham

Proper regulation of microbial-induced cytokines is critical to intestinal immune homeostasis. Acute stimulation of nucleotide-binding oligomerization domain 2 (NOD2), the Crohn’s disease–associated sensor of bacterial peptidoglycan, induces cytokines. However, chronic NOD2 stimulation in macrophages decreases cytokines upon pattern recognition receptor (PRR) restimulation; cytokine attenuation to PPR stimulation is similarly observed in intestinal macrophages. The role for the transcriptional repressors Twist1 and Twist2 in regulating PPR-induced cytokine outcomes is poorly understood and has not been reported for NOD2.

We found that Twist1 and Twist2 were required for optimal cytokine downregulation during acute and, particularly, chronic NOD2 stimulation of human macrophages. Consistently, Twist1 and Twist2 expression was increased after chronic NOD2 stimulation; this increased expression was IL-10 and TGF-β dependent. Although Twist1 and Twist2 did not coregulate each other’s expression, they cooperated to enhance binding to cytokine promoters after chronic NOD2 stimulation. Moreover, Twist1 and Twist2 contributed to enhanced expression and promoter binding of the proinflammatory inhibitor c-Maf and the transcriptional repressor Bmi1. Restoring c-Maf and Bmi1 expression in Twist-deficient macrophages restored NOD2-induced cytokine downregulation. Furthermore, with chronic NOD2 stimulation, Twist1 and Twist2 contributed to the decreased expression and cytokine promoter binding of the transcriptional activators activating transcription factor 4, C/EBPα, Runx1, and Runx2. Knockdown of these transcriptional activators in Twist-deficient macrophages restored cytokine downregulation after chronic NOD2 stimulation. Finally, NOD2 synergized with additional PRRs to increase Twist1 and Twist2 expression and Twist-dependent pathways. Therefore, after chronic NOD2 stimulation Twist1 and Twist2 coordinate the regulation of both transcriptional activators and repressors, thereby mediating optimal cytokine downregulation.

H uman nucleotide-binding oligomerization domain 2 (NOD2), an intracellular sensor of bacteria-derived muramyl dipeptide (MDP; a component of peptidoglycan), confers the greatest genetic risk of developing Crohn’s disease (CD), a disease of chronic intestinal inflammation (1). When peripheral monocytes enter mucosal sites, such as the intestinal lamina propria, they are continuously exposed to bacterial products, including the NOD2 ligand, peptidoglycan/MDP (2, 3). Initial NOD2 stimulation results in cytokine secretion (3–5). However, ongoing NOD2 stimulation significantly downregulates cytokine secretion upon restimulation through pattern recognition receptors (PRRs) (3–7). This downregulation is impaired in individuals with CD-associated NOD2 polymorphisms (4, 5). Cytokine secretion in intestinal macrophages is similarly attenuated upon PRR stimulation (8), which is important for intestinal immune homeostasis. Moreover, chronic MDP administration to mice in vivo attenuates subsequent experimental colitis (6), thereby demonstrating the beneficial effects of chronic NOD2 stimulation in intestinal immune regulation.

Mechanisms contributing to cytokine downregulation after chronic NOD2 stimulation in human myeloid–derived cells include the upregulation of the intracellular inhibitors IRAK-M (4), Tollip (3), and IRF4 (6, 9), and the Tyro3, Axl, and Mer tyrosine kinase receptors (10); the NF-κB–dependent upregulation of the transcriptional repressor activating transcription factor (ATF)3 (3); and the secretion of the inhibitory mediators IL-10 and TGF-β (5). Each of these mechanisms contributes only partially to cytokine downregulation and is operational to varying degrees in different individuals (e.g., IRAK-M) (4, 11). Given the dramatic alterations in macrophage functions and importance of downregulating PRR-initiated pathways upon chronic microbial stimulation, we hypothesized that additional critical mechanisms mediating these changes have yet to be identified, including those involving transcriptional regulators.

Twist1 and Twist2 are basic helix-loop-helix transcriptional repressors that bind to E boxes in gene promoters, acting as master regulators in a variety of biological processes, including organogenesis, osteogenesis, cancer progression, and hematopoietic cell development (12–14). As such, Twist1+/− mice are embryonic lethal because of a variety of developmental defects (15). Mutations in Twist1 are associated with Saethre–Chotzen syndrome (16, 17), an autosomal dominant disorder characterized by craniofacial and limb anomalies. Although the major focus on Twist function has been in the context of the critical cellular processes described above, there is evidence for a role for Twists in regu-
lating inflammation (14, 18–22). Twist2−/− mice demonstrate increased myeloid lineage development (14). Moreover, Twist2−/− mice or Twist1−/−/Twist2−/− mice demonstrate increased proinflammatory cytokines associated with increased NF-κB pathway signaling and perinatal death and defects in the type I IFN–mediated suppression of proinflammatory cytokines in macrophages (18, 22). In T cells, Twist1 limits Th1, Th17, and T follicular helper cell development (20, 21). However, the role and mechanisms through which Twist1 and Twist2 regulate PRR-induced cytokine outcomes is poorly understood; Twist regulation of NOD2-induced outcomes has not been reported. Given the repressive functions of the Twist proteins and evidence for their ability to limit inflammation in select situations, we hypothesized that Twist1 and/or Twist2 would contribute to downregulating cytokines during both acute and chronic NOD2 stimulation in primary human macrophages.

We found that Twist1 and Twist2 were required for the downregulation of cytokines during both acute and, in particular, chronic NOD2 stimulation of human monocyte–derived macrophages (MDMs). Consistently, Twist1 and Twist2 were each significantly upregulated after prolonged NOD2 stimulation; this upregulation required autocrine IL-10 and TGF-β and was defective in MDMs from CD-associated NOD2 risk carriers. Binding of the upregulated Twist1 and Twist2 transcriptional repressors to cytokine promoters was increased in a cooperative manner after chronic NOD2 stimulation. Moreover, Twist1 and Twist2 upregulated the expression and promoter binding of additional inhibitory transcriptional regulators, including c-Maf and Bmi1, while decreasing expression and promoter binding of additional inhibitory transcription factors, including ATF4, C/EBPα, Runx1, and Runx2. Complementation of the reduced c-Maf and Bmi1 expression, or reduction in the upregulated ATF4, C/EBPα, Runx1, and Runx2 under Twist-deficient conditions were each sufficient to restore cytokine downregulation under chronic NOD2 stimulation conditions. Therefore, Twist1 and Twist2 contribute to cytokine downregulation during chronic NOD2 stimulation through the coordination of the reciprocal expression and cytokine promoter binding of additional transcriptional repressors and activators.

Materials and Methods

Primary MDM culture and genotyping

Informed consent was obtained as approved by the Yale University Institutional Review Board. Monocytes were purified from healthy individuals or CD patients (Supplemental Fig. 1E) and differentiated to MDMs for 7 d with 10 ng/ml M-CSF (Shenandoah Biotechnology, Warwick, PA) as in Ref. 4. We performed NOD2 genotyping by TaqMan (Applied Biosystems, Foster City, CA) or Sequenom platform (Sequenom, San Diego, CA).

mRNA expression

Total RNA was isolated and reverse transcribed, and quantitative PCR was performed as previously described (4) with normalization to GAPDH. Primers are available upon request.

Myeloid cell stimulation

For tolerance induction in vitro, human MDMs (0.5 × 10^6) were pretreated with 100 μg/ml MDP (Bachem, King of Prussia, PA) for 48 h prior to extensive wash and retrieved for 24 h with 100 μg/ml MDP. In some cases, anti–IL-10 or anti–TGF-β–neutralizing Abs (R&D Systems, Minneapolis, MN) or lipid A (Peptide International, Louisville, KY) was used. Supernatants were assayed for cytokine secretion per manufacturer instructions using the following Abs: TNF, IL-6, IL-8, IL-10 (BD Biosciences, San Jose, CA), or IL-12 (eBioscience, San Diego, CA).

Protein expression analysis

Western blot analysis was performed as in Ref. 4 using Abs to Twist1/2 (Ab50887; Abcam, Cambridge, MA), c-Maf (sc7866; Santa Cruz Biotechnology, Santa Cruz, CA), Bmi1 (05-1322; EMD Millipore, Billerica, MA), or anti-GAPDH (EMD Millipore).

Transfection of small interfering RNAs and plasmids

Primary human MDMs were transfected with 100 nM scrambled or ON-TARGETplus SMARTpools small interfering RNA (siRNA) against Twist1, Twist2, c-Maf, Bmi1, ATF4, C/EBPα, Runx1, or Runx2 (Dharmacon, Lafayette, CO) (four pooled siRNAs for each gene) or with 2 μg pT3-EF1α-Bmi1 [Addgene plasmid 31783 kindly deposited by X. Chen (23)], c-Maf (GeneCopeia, Rockville, MD), or empty vector using Amaxa nucleofector technology (Amaxa, San Diego, CA).

Chromatin immunoprecipitation

Chromatin immunoprecipitation (ChIP) analysis of MDMs was performed according to a modified protocol (3). Primers were designed to amplify
Twist1 and Twist2 are required for optimal downregulation
of cytokines upon acute and chronic NOD2 stimulation

To elucidate the role of Twist1 and Twist2 in cytokine downregulation with acute NOD2 stimulation in human MDMs, we used siRNA to reduce the expression of Twist1 and Twist2, alone and in combination. We assessed expression of each Twist with each knockdown condition and found selective downregulation of the targeted Twist (Supplemental Fig. 1A), such that Twist1 and Twist2 did not coregulate the expression of the other. We further confirmed knockdown of Twist1 and Twist2 proteins (Supplemental Fig. 1B). Knockdown of Twist1 and Twist2, alone and in combination, led to increased secretion of the proinflammatory cytokines TNF, IL-6, IL-8, IL-12p40 (Fig. 1), and IL-1β (Supplemental Fig. 1C), as well as the anti-inflammatory mediators IL-10 (Fig. 1) and IL-1Ra (Supplemental Fig. 1C), upon acute NOD2 stimulation of human MDMs. We next evaluated the role of Twist1 and Twist2 in the cytokine downregulation observed after chronic NOD2 stimulation. We previously found that stimulation of NOD2 for 48 h is optimal for downregulating cytokine secretion upon restimulation through NOD2 or other PRRs (4). We used 100 μg/ml MDP as this concentration approximates muramic acid stool levels (24), has been used by us and others, and results in optimal cytokine downregulation after chronic NOD2 stimulation (3–5). Upon knockdown of Twist1 or Twist2 after initiation of chronic NOD2 stimulation and then restimulating through NOD2 (Fig. 1A), there was significant reversal in the downregulation of both proinflammatory cytokines and anti-inflammatory cytokines (Fig. 1B). Reversal was further enhanced when Twist1 and Twist2 were knocked down in combination (Fig. 1B). Taken together, Twist1 and Twist2 cooperate to downregulate cytokines upon both acute and chronic NOD2 stimulation of human MDMs.

Expression of Twist1 and Twist2 increases with chronic NOD2 stimulation in human MDMs in an IL-10– and TGF-β–dependent manner and fails to increase in CD NOD2 risk carriers

Given the role for Twist1 and Twist2 in downregulating cytokines upon chronic NOD2 stimulation, we questioned whether Twist expression is upregulated with chronic NOD2 stimulation of human MDMs. Twist1 and Twist2 mRNA expression was enhanced in 48-h MDP-pretreated MDMs and further increased 4 h after restimulation (Fig. 2A). Twist1/2 protein expression was similarly increased after restimulation of 48-h MDP-pretreated MDMs (Fig. 2B). We next sought to define the mechanisms upregulating Twist1 and Twist2 expression upon chronic NOD2 stimulation in human MDMs. We have previously shown that the early secretion of IL-10 and TGF-β is required for subsequent pro- and anti-inflammatory cytokine downregulation during chronic NOD2 stimulation (5). Furthermore, recent studies have demonstrated a necessity for IL-10R on intestinal macrophages for the generation of anti-inflammatory macrophages (25, 26), thereby highlighting the importance of IL-10 in conditioning the inhibitory mechanisms generated in intestinal macrophages. We found that autocrine IL-10 and TGF-β were each required, and moreover cooperated with each other, for optimal upregulation in Twist1 and Twist2 expression.
Twist2 expression upon chronic NOD2 stimulation in human MDMs (Fig. 2C). Finally, we questioned whether MDMs from CD patients similarly upregulated Twist1 and Twist2 upon chronic NOD2 stimulation (see Supplemental Fig. 1E for patient characteristics). Twist1 and Twist2 expression in MDMs from wild-type NOD2 CD patients was induced to a similar degree as in MDMs from healthy controls (Fig. 2D). Furthermore, the range of Twist1 and Twist2 expression upon chronic NOD2 stimulation in these individuals was not significantly different (Supplemental Fig. 1D). In contrast, Twist1 and Twist2 expression failed to increase after chronic NOD2 stimulation of MDMs from CD loss-of-function NOD2 risk carriers (Fig. 2D). MDMs from these NOD2 risk carriers were responsive to stimulation through alternative PRRs, such that Twist1 and Twist2 expression increased in these MDMs upon chronic lipid A treatment (Fig. 2D). Therefore, Twist1 and Twist2 increase in an IL-10– and TGF-β–dependent manner upon chronic NOD2 stimulation.

Twist1 and Twist2 cooperate with each other for the enhanced binding to cytokine promoters observed after chronic NOD2 stimulation

Twist1 and Twist2 transcriptional repressors were upregulated with chronic NOD2 stimulation (Fig. 2) and were required for optimal cytokine downregulation after chronic NOD2 stimulation (Fig. 1). We therefore questioned whether the binding of these transcriptional repressors to cytokine promoters was enhanced after chronic NOD2 stimulation, and if so, whether Twist1 and Twist2 cooperated with each other for this enhanced binding. Twist1 and Twist2 binding to both proinflammatory and anti-inflammatory cytokine promoters increased particularly 48 h after NOD2 stimulation and even more so upon restimulation of MDP-pretreated MDMs (Fig. 3A). Upon examining restimulated MDP-pretreated MDMs where Twist1 and Twist2 binding to cytokine promoters was most enriched, we observed that knockdown of each Twist affected binding not only of itself but also of the other Twist protein to cytokine promoters (Fig. 3B). Taken together, chronic NOD2 stimulation results in significantly enriched and cooperative binding of the transcriptional repressors Twist1 and Twist2 to proinflammatory and anti-inflammatory cytokine promoters.

Twist1- and Twist2-dependent upregulation of c-Maf and Bmi1 is critical for cytokine downregulation after chronic NOD2 stimulation

In addition to their direct suppressor activity, transcriptional repressors, including the Twist proteins, can both increase the expression of additional inhibitory molecules and suppress the expression of essential

![FIGURE 3](https://www.jimmunol.org/)

**FIGURE 3.** Twist1 and Twist2 cooperate with each other for enhanced binding to cytokine promoters after chronic NOD2 stimulation. (A) MDMs (n = 4) were left untreated or pretreated with 100 μg/ml MDP for 48 h and then treated with 100 μg/ml MDP for an additional 4 h (acute). (B) MDMs (n = 4) were left untreated (for acute) or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled, Twist1, or Twist2 siRNA alone or in combination, and 24 h later (total 48-h MDP pretreatment), MDMs were treated with 100 μg/ml MDP for an additional 4 h (acute). (A and B) Recruitment of Twist1 and Twist2 to cytokine gene promoters was assessed by ChIP. Fold enrichment normalized to untreated, scrambled siRNA–transfected cells + SEM. (B) Statistical significance above the knockdown sample bars is compared with its corresponding scrambled siRNA sample. *p < 0.05, **p < 0.01, ***p < 0.001. tx, treatment.
activating molecules; in combination, these enable optimal suppressive outcomes (12). We therefore first investigated whether Twist1 and Twist2 might be contributing to cytokine downregulation after chronic NOD2 stimulation through upregulating inhibitory molecules previously identified to play a role in NOD2-induced cytokine downregulation. However, Twist1 and Twist2 knockdown, either alone or in combination, did not impair the upregulation of NFκB1, ATF3, IRAK-M, or Tollip after chronic NOD2 stimulation (Supplemental Fig. 2A). We further examined proximal signaling pathways that are induced upon acute NOD2 stimulation and found that combined Twist1 and Twist2 knockdown did not regulate acute NOD2–induced activation of the ERK, p38, or JNK pathways (Supplemental Fig. 2B) or the early secretion of IL-1β (Supplemental Fig. 2C), which we have found to be a measure of NOD2-induced caspase-1 activation (27, 28).

Twist1 and Twist2 have not been well studied in PRR-induced cytokine regulation. However, they have been well investigated in carcinogenesis, osteogenesis, and hematopoietic cell development. We therefore questioned whether inhibitory molecules upregulated by Twist1 and/or Twist2 identified through these other processes might be similarly Twist dependent upon chronic NOD2 stimulation in human MDMs and thereby contribute to the cytokine downregulation observed. During myeloid lineage development, Twist2 can upregulate the proinflammatory transcriptional inhibitor c-Maf (14); Twist2 can also bind to the c-Maf promoter with LPS treatment in mouse macrophages (29). However, c-Maf regulation of PRR-initiated pathways has not been well defined. Twist1 regulates Bmi1 expression and cooperates with Bmi1 in repressor functions during epithelial–mesenchymal transition relevant to cancer metastasis (30); a role for Bmi1 in PRR signaling and outcomes is poorly understood. Furthermore, Twist regulates PI3K pathways (31), and Akt1 can contribute to an anti-inflammatory macrophage phenotype (32). We found that c-Maf, Bmi1, and Akt1 were upregulated with chronic NOD2 stimulation (Fig. 4A). However, only c-Maf and Bmi1 transcript upregulation was Twist1 and Twist2 dependent (Fig. 4B); c-Maf and Bmi1 protein

FIGURE 4. Upon chronic NOD2 stimulation, expression and cytokine promoter binding of the anti-inflammatory transcription factors c-Maf and Bmi1 are upregulated in a Twist-dependent manner. (A) MDMs (n = 8) were left untreated or pretreated with 100 μg/ml MDP for 48 h and then treated with 100 μg/ml MDP for 4 h (acute). Fold increase in c-Maf, Bmi1, and Akt1 mRNA was normalized to untreated MDMs + SEM. (B) MDMs (n = 8) were left untreated (for acute) or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled, Twist1, or Twist2 siRNA, alone or in combination, and 24 h later (total 48 h after MDP pretreatment), MDMs were treated with 100 μg/ml MDP for 4 h (acute) and assessed for c-Maf, Bmi1, and Akt1 mRNA expression. Fold mRNA expression normalized to untreated, scrambled siRNA–transfected MDMs + SEM. (C) MDMs were left untreated or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled or a combination of Twist1 and Twist2 siRNA, and 24 h later (total 48 h MDP pretreatment), MDMs were treated with 100 μg/ml MDP for an additional 8 h (acute), and c-Maf or Bmi1 expression was assessed by Western blot. GAPDH was assessed as a loading control. (D) MDMs were left untreated (for acute) or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled or a combination of Twist1 and Twist2 siRNA, and 24 h later (total 48 h after MDP pretreatment), MDMs were treated with 100 μg/ml MDP for an additional 4 h (acute). Recruitment of c-Maf (n = 4) and Bmi1 (n = 5) to cytokine gene promoters was assessed by ChIP. Fold enrichment normalized to untreated, scrambled siRNA–transfected MDMs + SEM. (B and C) Statistical significance above the knockdown sample bars is compared with its corresponding scrambled siRNA sample. *p < 0.05, **p < 0.01, ***p < 0.001, †p < 1 × 10⁻⁴, ††p < 1 × 10⁻⁵, tx, treatment.
upregulation was similarly Twist dependent (Fig. 4C). Furthermore, the binding of c-Maf and Bmi1 to both proinflammatory and anti-inflammatory cytokine promoters was enriched with chronic NOD2 stimulation (Fig. 4D); this enhanced promoter binding was Twist1 and Twist2 dependent (Fig. 4D). Importantly, through c-Maf and Bmi1 knockdown (Fig. 5A), we established that c-Maf and Bmi1 each contributed to the cytokine downregulation observed after chronic NOD2 stimulation (Fig. 5B). Moreover, they cooperated with each other for optimal cytokine downregulation (Fig. 5B). Finally, to clearly establish the role of c-Maf and Bmi1 in Twist-dependent contributions to chronic NOD2-induced cytokine downregulation in MDMs, we restored both c-Maf and Bmi1 expression in Twist-deficient MDMs to levels similar to those observed after chronic NOD2 stimulation (Fig. 4C). Despite the absence of Twist1 and Twist2, reconstitution of each c-Maf and Bmi1 could partially restore the cytokine downregulation observed after chronic NOD2 stimulation (Fig. 5C). Moreover, the restoration was further improved with combined expression of both c-Maf and Bmi1 (Fig. 5C). Therefore, one mechanism through which Twist1 and Twist2 downregulate cytokines after chronic NOD2 stimulation is through the upregulation in expression and cytokine promoter binding of the transcriptional repressors c-Maf and Bmi1.

Twist1 and Twist2 downregulate the expression and binding to cytokine promoters of the transcriptional activators ATF4, C/EBPα, Runx1, and Runx2

Twist1 and Twist2 can both decrease the expression and compete with promoter binding of activating transcription factors in osteogenesis, carcinogenesis, and myeloid differentiation (12). We therefore hypothesized that Twist1 and Twist2 might be similarly downregulating activating transcription factors upon chronic NOD2 stimulation where cytokines are dramatically reduced. How activating transcription factors are regulated with chronic NOD2 stimulation has not been well defined. We therefore considered the Twist-regulated activating transcription factors defined in other cellular processes. Twist1 can attenuate ATF4 binding to the osteocalcin promoter in osteoclasts (33). Furthermore, Twist1 and Twist2 can inhibit Runx2 transactivation functions during osteoblast differentiation (34). Moreover, Twist2 can negatively regulate myeloid lineage differentiation by interacting with and inhibiting the transcription factors Runx1 and C/EBPα (14). Twist proteins can also regulate Akt2 expression in breast cancer cells (35). To our knowledge, roles for ATF4, C/EBPα, Runx1, and Runx2 in NOD2-induced outcomes have not been reported, and we therefore first examined the regulation of each of these transcription factors with acute and chronic NOD2 stimulation of MDMs.

With NOD2 stimulation of MDMs, ATF4, C/EBPα, Runx1, Runx2, and Akt2 were each upregulated acutely but downregulated by 48 h, and they failed to increase on restimulation of NOD2 (Fig. 6A), consistent with the attenuated cytokines at this time. We further assessed the Twist dependency for these downregulated transcription factors and found that ATF4, C/EBPα, Runx1, and Runx2 downregulation was dependent on the combined expression of Twist1 and Twist2 (Fig. 6B). Akt2 downregulation after chronic NOD2 stimulation, in contrast, was Twist independent (Fig. 6B). We therefore pursued the role and regulat

**FIGURE 5.** Uregulated Bmi1 and c-Maf cooperate to mediate Twist-dependent cytokine downregulation upon chronic NOD2 stimulation of human MDMs. (A) MDMs (n = 4) were transfected with scrambled, Bmi1, or c-Maf siRNA for 24 h. Fold mRNA expression normalized to scrambled siRNA–transfected MDMs + SEM. (B) MDMs (n = 4) were left untreated (for acute) or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled, c-Maf, or Bmi1 siRNA, alone or in combination, and 24 h later (total 48-h MDP pretreatment), MDMs were stimulated with 100 μg/ml MDP for 24 h (acute), and cytokine secretion was assessed ± SEM. Numbers on the bars are the ratios of cytokine secretion upon MDP treatment of the corresponding pretreated versus nonpretreated MDMs. Statistical significance above the knockdown sample bars is **p < 0.001, †p < 0.01, *p < 0.05, **p < 0.01, ***p < 0.001, ††p < 1 × 10^{-4}, †††p < 1 × 10^{-5}. scr, scrambled; tx, treatment.
lation of the Twist-dependent transcription factors. ATF4, C/EBPα, Runx1, and Runx2 bound to cytokine promoters with acute NOD2 stimulation, and this binding was dramatically reduced after chronic NOD2 stimulation, consistent with the reduced cytokines observed under these conditions (Fig. 6C). Moreover, upon Twist1 and Twist2 knockdown during chronic NOD2 stimulation, the binding of these transcription factors to cytokine promoters failed to undergo reduction relative to scrambled knockdown cells, consistent with the impaired cytokine downregulation (Fig. 6C). Finally, to ensure that the relative increase in expression and binding of ATF4, C/EBPα, Runx1, and Runx2 to cytokine promoters in Twist-deficient MDMs was contributing to the failure to downregulate cytokines upon chronic NOD2 stimulation, we used siRNA to each of the transcription factors (Fig. 7A), alone and in combination. Reduced expression of each ATF4, C/EBPα, Runx1, and Runx2 partially restored cytokine downregulation, and combined knockdown of these Twist-regulated transcription factors fully restored cytokine downregulation in Twist-deficient macrophages after chronic NOD2 stimulation (Fig. 7B). Cells were viable under these conditions (data

**FIGURE 6.** Expression and cytokine promoter binding of the transcriptional activators ATF4, C/EBPα, Runx1, and Runx2 is reduced in a Twist-dependent manner during chronic NOD2 stimulation. (A) MDMs (n = 8) were left untreated or pretreated with 100 μg/ml MDP for 48 h, and then MDMs were treated with 100 μg/ml MDP for 4 h (acute). Fold change in ATF4, C/EBPα, Runx1, Runx2, and Akt2 mRNA normalized to untreated MDMs + SEM. (B) MDMs (n = 8) were left untreated (for acute) or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled, Twist1, or Twist2 siRNA, alone or in combination, and 24 h later (total 48-h MDP pretreatment), MDMs were stimulated with 100 μg/ml MDP for 4 h (acute) and assessed for ATF4, C/EBPα, Runx1, Runx2, and Akt2 mRNA expression. Fold mRNA expression normalized to untreated, scrambled siRNA–transfected MDMs + SEM. (C) MDMs (n = 4–6) were left untreated (for acute) or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled or a combination of Twist1 and Twist2 siRNA, and 24 h later (total 48-h MDP pretreatment), MDMs were treated with 100 μg/ml MDP for an additional 4 h (acute). Recruitment of ATF4, C/EBPα, Runx1, and Runx2 to cytokine gene promoters was assessed by ChIP. Fold enrichment normalized to untreated, scrambled siRNA–transfected cells + SEM. (B and C) Statistical significance above the knockdown sample bars is compared with its corresponding scrambled siRNA sample. *p < 0.01, **p < 0.001, ***p < 0.0001, †p < 1 × 10⁻⁴. tx, treatment.
not shown). Therefore, Twist1 and Twist2 contribute to the downregulation in expression and promoter binding of various transcription factors, in particular ATF4, C/EBPα, Runx1, and Runx2, which in turn is necessary for optimal cytokine downregulation after chronic NOD2 stimulation in MDMs.

**NOD2 synergizes with TLR2, TLR4, and TLR9 to enhance Twist1 and Twist2 upregulation and induction of Twist-dependent pathways**

Because intestinal macrophages are exposed to multiple PRRs, we next assessed whether chronic stimulation of other PRRs similarly upregulates Twist1 and Twist2 expression in human MDMs, and whether these other PRRs cooperate with NOD2 to regulate Twist1- and Twist2-mediated outcomes. Similar to chronic NOD2 stimulation, cytokines are downregulated upon restimulation of MDM after chronic stimulation of TLR2, TLR4, or TLR9 (Supplemental Fig. 3A). We found that upon pretreatment through TLR2, TLR4, or TLR9, and then restimulation of each respective TLR, Twist1 and Twist2 expression was increased (Supplemental Fig. 3B). The Twist-dependent pathways we had identified were similarly regulated under these conditions, with upregulation of the transcriptional repressors c-Maf and Bmi1 (Supplemental Fig. 3C) and downregulation of the transcriptional activators ATF4, C/EBPα, Runx1, and Runx2 (Supplemental Fig. 3D). Although low-dose MDP treatment synergized with each of the TLR ligands to increase expression of cytokines during acute treatment, cytokines were downregulated upon chronic stimulation of NOD2 with each of the TLRs (Supplemental Fig. 3A). Moreover, chronic MDP treatment synergized with each TLR to upregulate Twist1 and Twist2 and the transcriptional repressors c-Maf and Bmi1 (Supplemental Fig. 3B, 3C). Taken together, under the chronic microbial ligand exposure that occurs in the intestinal environment, NOD2 can synergize with other PRRs to upregulate Twist1 and Twist2 expression and Twist-dependent mechanisms that lead to cytokine downregulation.

**Discussion**

In this study, we demonstrate that Twist1 and Twist2 contribute to the downregulation of proinflammatory cytokines upon acute and particularly chronic NOD2 stimulation of human MDMs. Twist1 and Twist2 expression increased with chronic NOD2 stimulation, consistent with the important role for these transcriptional repressors in the downregulation of cytokines observed after prolonged NOD2 stimulation. Twist upregulation is similarly observed in MDMs from CD patients but is impaired in MDMs from CD NOD2 risk carriers. Early secreted IL-10 and TGF-β were critical for Twist1 and Twist2 expression upregulation with chronic NOD2 stimulation. Binding of Twist1 and Twist2 to cytokine promoters was particularly enhanced after chronic NOD2 stimulation, and the two proteins cooperated with each other for optimal promoter binding. In addition to the direct binding of the Twist1 and Twist2 transcriptional repressors to cytokine promoters, they also orchestrated a coordinated program in which the expression and cytokine promoter binding of various activating transcription factors including c-Maf and Bmi1 were increased, whereas the expression and cytokine promoter binding of various repressing transcription factors such as Twist1 and Twist2 were reduced. These combined Twist-mediated mechanisms contributed to the ability of Twist1 and Twist2 to downregulate NOD2-induced cytokines (Supplemental Fig. 4). Furthermore, NOD2 could synergize with various PRRs to mediate these outcomes, consistent with the cooperative role for NOD2 with other PRRs and cytokines in enhancing downstream immune outcomes (36–42). Therefore, we now elucidate a clear role for Twist1- and Twist2-mediated mechanisms in downregulating cytokines upon acute and chronic NOD2 stimulation of primary human MDMs.

A role for Twist repressors in PRR-induced outcomes has been relatively unexplored. However, Twist1- and Twist2-mediated transcriptional mechanisms identified to regulate suppression in biological processes such as osteogenesis, hematopoiesis, and carcinogenesis provided the opportunity to now dissect if these pathways are Twist dependent and similarly or differentially regulate outcomes upon PRR stimulation of human macrophages. A number of the downstream molecules contributing to Twist-dependent regulation in these other cell processes have not been

---

**FIGURE 7.** ATF4, C/EBPα, Runx1, and Runx2 downregulation contributes to Twist-mediated cytokine downregulation after chronic NOD2 stimulation. (A) MDMs (n = 4) were transfected with scrambled, ATF4, C/EBPα, Runx1, or Runx2 siRNA for 24 h. Fold mRNA expression normalized to scrambled, siRNA-transfected MDMs + SEM. (B) MDMs (n = 4) were left untreated (for acute) or pretreated with 100 μg/ml MDP for 24 h and then transfected with scrambled or a combination of Twist1 and Twist2 siRNA ± ATF4, C/EBPα, Runx1, or Runx2 siRNA alone or in combination, and 24 h later (total 48-h MDP pretreatment), MDMs were stimulated with 100 μg/ml MDP for 24 h (acute), and cytokine secretion was assessed. Numbers on the bars are the ratios of cytokine secretion to scrambled; tx, treatment.
previously implicated in NOD2-induced outcomes. One such example is the role we now identify for Twist-dependent c-Maf regulation in downregulating cytokines after chronic NOD2 stimulation. c-Maf has been predominantly studied in the context of T cell differentiation, in particular Tr1 cells (43). However, a few studies have also identified a role for c-Maf as an anti-inflammatory transcription factor in myeloid cells; c-Maf downregulates transcriptional activation of proinflammatory cytokines while upregulating transcriptional activation of IL-10 in myeloid-derived cells (44, 45). In contrast, we found that in primary human macrophages, c-Maf downregulated both pro- and anti-inflammatory cytokines upon NOD2 stimulation (Fig. 5). Studies on Bmi1 have focused largely on its contributions to carcinogenesis. The role of Bmi1 in regulating PRR-induced outcomes has been poorly defined. To our knowledge, there is only one such study; this study identified a role for Bmi1 in suppressing IL-10 in mouse macrophages (46). We now define a broader role for Bmi1 in suppressing a range of both pro- and anti-inflammatory cytokines upon PRR stimulation, with a Twist-dependent role for Bmi1 in the robust downregulation of cytokines after chronic PRR stimulation (Fig. 5). Although neither Akt1 nor Akt2 was regulated by Twist proteins, we observed that Akt1 was upregulated (Fig. 4A), whereas Akt2 was downregulated (Fig. 6A) with chronic NOD2 stimulation. This pattern of expression regulation is consistent with the role of Akt1 in polarization to pro-inflammatory macrophages and of Akt2 in polarization to proinflammatory macrophages (32).

We identified a number of transcription factors, including ATF4, C/EBPα, Runx1, and Runx2 whose expression and binding to cytokine promoters was upregulated with acute NOD2 stimulation but downregulated in a Twist-dependent manner with chronic NOD2 stimulation. Restoring the downregulation of these transcription factors in Twist-deficient MDMs was able to restore the cytokine downregulation observed with chronic NOD2 stimulation. Runx1 and Runx2 have been well studied in cell proliferation and differentiation (47), and C/EBPα has been identified as a lineage-specific transcription factor in the hematopoietic system (48). However, the role of these transcription factors in PRR-induced outcomes has been poorly defined. We now identify each of these transcription factors as being essential in the induction of cytokines after acute NOD2 stimulation; their downregulation after chronic NOD2 stimulation contributes to the overall cytokine downregulation under these conditions. Limited studies have examined the role of ATF4 downstream of PRRs. ATF4 was found to contribute to cytokine secretion upon acute TLR4 stimulation (49). In contrast, upon stimulation of macrophages through TLR4, TRIF-dependent signaling led to the downregulation of the ATF4/C/EBP homology protein branch of the unfolded protein response (50). We similarly observed differential regulation of ATF4 with acute and chronic NOD2 stimulation. Taken together, these studies elucidate an important role for Twist1 and Twist2 in regulating NOD2- and PRR-induced cytokine secretion under both the initial acute cytokine stimulation as well as under the chronic stimulatory conditions that are present in the intestinal environment, thereby providing insight into the inhibitory mechanisms critical for regulating the CD-associated NOD2.

Disclosures
The authors have no financial conflicts of interest.

References

Downloaded from http://www.jimmunol.org/ by guest on April 14, 2017
Supplemental Figure 1. Twist1 and Twist2 siRNA effectively decrease Twist mRNA and protein expression. (A) Human MDMs (n=8) were transfected with scrambled, Twist1 or Twist2 siRNA, and 48h later MDMs were assessed for Twist1 or Twist2 RNA expression relative to scrambled siRNA-transfected cells + SEM. (B) Human MDMs were pre-treated with 100μg/ml MDP for 24h, then transfected with scrambled, or a combination of Twist1 and Twist2 siRNA, and 24h later (total 48h MDP pre-treatment), MDMs were treated with 100μg/ml MDP for an additional 8h. Western blot was conducted with an antibody detecting both Twist1 and Twist2. Representative Western blot from 1 of 4 individuals. GAPDH is used as a loading control. (C) Human MDMs were left untreated (for acute) or pre-treated with 100μg/ml MDP for 24h, then transfected with scrambled, or combined Twist1 and Twist2 siRNA, and 24h later (total 48h MDP pre-treatment), MDMs were treated with 100μg/ml MDP for an additional 24h (acute). Supernatants were examined for cytokines. Mean + SEM for n=4. Numbers on the bars are the ratios of cytokine secretion upon MDP treatment of pre-treated versus non-pretreated MDMs. (D) MDP pre-treated/treated MDMs from WT NOD2 healthy controls (HC; n=8) and Crohn’s disease (CD) patients (n=8) shown in Figure 2D were assessed for Twist1 and Twist2 mRNA expression by CT values normalized to GAPDH and represented as a linear scale. Each symbol represents an individual. Horizontal line represents the mean. (E) Phenotype/genotype characteristics for Crohn’s disease patients studied in (D) and Figure 2D. *, p<0.05; **, p<0.01; ***, p<0.001; ††, p<1×10^{-5}.
Supplemental Figure 2. Twist1 and Twist2 do not contribute to upregulation of the intracellular inhibitory molecules NFκB1, ATF3, IRAK-M or Tollip, the activation of MAPK pathways or the early secretion of IL-1β. (A) MDMs (n=8) were left untreated (for acute) or pre-treated with 100μg/ml MDP for 24h, then transfected with scrambled, Twist1 or Twist2 siRNA, alone or in combination, and 24h later (total 48h after MDP pre-treatment), MDMs were treated with 100μg/ml MDP for 4h (acute) and assessed for NFκB1, ATF3, IRAK-M and Tollip mRNA expression. Fold mRNA expression normalized to untreated, scrambled siRNA-transfected MDMs + SEM. (B) MDMs (n=8) were transfected with scrambled or combined Twist1 or Twist2 siRNA. Cells were then treated with 100μg/ml MDP for 15 min. (Left): Representative flow cytometry with MFI values for phospho-kinases. (Right): Summary graphs for phospho-kinase induction + SEM. (C) MDMs (n=4) were transfected with scrambled or combined Twist1 or Twist2 siRNA. Cells were then pretreated with 0.5μg/ml IL-1Ra (blocks IL-1 consumption) and then treated with 100μg/ml MDP for 15 min. Supernatants were examined for IL-1β. **, p<0.01; ***, p<0.001; †, p<1×10^{-4}. Tx, treatment.
Supplemental Figure 3. Multiple PRRs regulate expression of Twist1 and Twist2 and downstream signals. (A) MDMs were left untreated (for acute) or pre-treated with 10μg/ml MDP, 0.1μg/ml Lipid A, 10μg/ml Pam3Cys or 1μg/ml CpG DNA alone or in combination for 48h, then treated with the same stimuli for an additional 24h (acute). Supernatants were examined for cytokines. Mean + SEM for n=4. (B-D) MDMs (n=8) were left untreated or pre-treated with 10μg/ml MDP, 0.1μg/ml Lipid A, 10μg/ml Pam3Cys or 1μg/ml CpG DNA alone or in combination for 48h, and then MDMs were treated with the same respective stimuli for an additional 4h (=chronic). Fold change in (B) Twist1, Twist2, (C) c-Maf, Bmi1, or (D) ATF4, C/EBPα, Runx1 or Runx2 mRNA normalized to untreated MDMs + SEM. Significance was assessed in treated relative to untreated cells, or as indicated. *, p<0.05; **, p<0.01; †, p<1×10⁻⁴. Tx, treatment.
Supplemental Figure 4. Schematic diagram of mechanisms for Twist1- and Twist2-mediated inhibition of cytokine secretion upon chronic NOD2 stimulation. Acute NOD2 stimulation in primary human MDMs results in increased secretion of both pro-inflammatory and anti-inflammatory cytokines. With prolonged NOD2 stimulation, Twist1 and Twist2 expression increases in an autocrine IL-10- and TGFβ-dependent manner. The transcriptional repressors Twist1 and Twist2 bind to cytokine promoters and contribute to the downregulation of cytokines after acute NOD2 stimulation, and in particular, after chronic NOD2 stimulation. Twist1 and Twist2 also upregulate the expression and cytokine promoter binding of the anti-inflammatory transcription factors c-Maf and Bmi1, which in turn downregulates cytokine secretion. At the same time, Twist1 and Twist2 downregulate the expression and cytokine promoter binding of various activating transcription factors, including ATF4, C/EBPα, Runx1 and Runx2, which also contributes to the downregulation of cytokine expression upon NOD2 stimulation. Furthermore, chronic stimulation of additional PRRs, including TLR2, TLR4, and TLR9, can similarly upregulate Twist1 and Twist2 expression and downstream pathways. Moreover, these PRRs can cooperate with NOD2 to further enhance the regulatory outcomes. Therefore, Twist1 and Twist2 coordinate reciprocal regulation in expression and cytokine promoter binding of transcriptional repressors (increased) and transcriptional activators (decreased), which ultimately contributes to the cytokine downregulation observed after chronic PRR stimulation.